Adverse events - incidence and grading according to CTCAE v 4.03
| Toxicity | Overall incidence, no. (%) | Grade 1 and 2, no. (%) | Grade 3 and 4, no. (%) |
|---|---|---|---|
| Hyperglycemia | 19 (79) | 19 (79) | |
| Fatigue | 19 (79) | 18 (75) | 1 (4) |
| Thrombocytopenia | 12 (50) | 12 (50) | |
| Headache | 11 (46) | 10 (43) | 1 (4) |
| Nausea | 10 (42) | 9 (38) | 1 (4) |
| Leukopenia | 9 (38) | 9 (38) | |
| ALT elevations | 8 (33) | 8 (33) | |
| AST elevations | 7 (29) | 7 (29) | |
| Bilirubin elevations | 5 (21) | 5 (21) | |
| Neutropenia | 5 (21) | 5 (21) | |
| Anemia | 5 (21) | 4 (17) | 1 (4) |
| Seizures | 5 (21) | 4 (17) | 1 (4) |
| Vomiting | 5 (21) | 4 (17) | 1 (4) |
| Thyroid toxicity | 4 (17) | 4 (17) | |
| Diarrhea | 4 (17) | 4 (17) | |
| Myalgias/Arthralgias | 3 (13) | 3 (13) | |
| Rash | 2 (8) | 2 (8) | |
| Pyrexia | 2 (8) | 2 (8) | |
| Lipase | 1 (4) | 1 (4) | |
| Amylase | 1 (4) | 1 (4) | |
| Mucositis | 1 (4) | 1 (4) |